News

Qubigen is pleased to announce its participation at JPM Week 2026 in San Francisco, the premier global gathering for biotech, pharma, medtech, and life sciences investment. JPM Week sees hundreds of industry leaders, investors, innovators and entrepreneurs convene each January in San Francisco, offering a unique moment to build partnerships, explore business development and invest in the future of healthcare innovation.   Qubigen Attendees Representing Qubigen at JPM Week wil

Qubigen is pleased to announce the signing of an agreement with QIMR Berghofer , one of Australia’s leading medical research institutes. The agreement establishes a framework to accelerate the development of novel drug candidates targeting tumorigenesis and cancer progression. By combining Qubigen’s computational modelling and quantum chemistry capabilities with QIMR Berghofer’s deep expertise in translational cancer biology, this partnership aims to illuminate new therapeuti

At Qubigen, we do something fundamentally different: we build AI Engines for drug design using our secure Federated AI Drug Design platform (FedAIDD). The platform allows our clients to generate truly novel compounds, without their data ever leaving its server. Qubigen’s FedAIDD can also predict reaction pathways and optimize for desired ADME-T properties, ultimately saving on med-chem costs. Our mission is to unlock the full potential of pharmaceutical data without compromi